Mackenzie Financial
BMY.RT

Mackenzie Financial’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Mackenzie Financial’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-52,913
Closed -$37K – 1235
2020
Q4 		$37K Hold
52,913
– – ﹤0.01% 1030
2020
Q3 		$119K Sell
52,913
-28,815
-35% -$82.3K ﹤0.01% 948
2020
Q2 		$293K Sell
81,728
-12,696
-13% -$45.8K ﹤0.01% 877
2020
Q1 		$359K Buy
+94,424
New +$311K ﹤0.01% 863

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Mackenzie Financial's BMY.RT Position: Q1 2021 in Review

Mackenzie Financial sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 52,913 shares — an estimated $37K sold.

Mackenzie Financial first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $359K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Mackenzie Financial reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Mackenzie Financial sold 52,913 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $37K.
  • Mackenzie Financial first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Mackenzie Financial's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $359K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Mackenzie Financial's 13F filing for Q1 2021, filed 14 May 2021.